ProCE Banner Activity

Experts Discuss Advances in the Use of BTK Inhibitors for the Treatment of Relapsed/Refractory MCL

Slideset Download

Download these slides from a live webinar to gain more insight about evidence-based integration of new and emerging BTK inhibitors into the treatment algorithm for patients with R/R MCL, including the regional impacts of the available data.

Released: January 17, 2023

Expiration: January 16, 2024

Begin Activity

Share

Faculty

Julie M. Vose

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Marco Ladetto

Marco Ladetto, MD

Associate Professor
Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale
Vercelli/Novara/Alessandria, Piedmont, Italy
Director of Hematology Oncology
SCDU Ematologia
AO SS Antonio E Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy

Max Topp

Max Topp, MD

Professor
Head of Hematology

Department of Hematology
Universitätsklinikum Würzburg
Würzburg, Germany

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Lilly

Program Director Disclosure

Program Director

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

Julie M. Vose, MD, MBA: consultant/advisor/speaker: AbbVie, AstraZeneca, Bristol Myers Squibb, Caribou, Daiichi Sankyo, Genentech, Kite, Lilly, MEI Pharma, MorphoSys, Pharmacyclics, Seattle Genetics.

Faculty Disclosure

Primary Author

Marco Ladetto, MD

Associate Professor
Dipartimento di Medicina Traslazionale
Università del Piemonte Orientale
Vercelli/Novara/Alessandria, Piedmont, Italy
Director of Hematology Oncology
SCDU Ematologia
AO SS Antonio E Biagio e Cesare Arrigo
Alessandria, Piedmont, Italy

Marco Ladetto, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, Amgen, AstraZeneca, Eusapharma, Gentili, Gilead/Kite, Incyte, Johnson & Johnson, Jazz, Lilly, Regeneron, Roche.

Max Topp, MD

Professor
Head of Hematology

Department of Hematology
Universitätsklinikum Würzburg
Würzburg, Germany

Max Topp, MD consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, Janssen, Kite, Roche.